|
lon:opti
|
19679023
|
Apr 21st, 2024 12:00AM
|
OptiBiotix Health Plc
|
2.0K
|
15.00
|
Open
|
|
Apr 21st, 2024 08:51AM
|
Apr 21st, 2024 08:51AM
|
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
|
Open
|
Biotechnology, Life sciences, Human micro biome, Cholesterol management, Disease prevention, Obesity prevention, Obesity management, Diabetes prevention, and Health & wellbeing
|
Open
|
|
York
|
|
GB
|
YO10 5DG
|
|
OptiBiotix Health
|
|
|
|
lon:opti
|
19679023
|
Apr 20th, 2024 12:00AM
|
OptiBiotix Health Plc
|
2.0K
|
15.00
|
Open
|
|
Apr 20th, 2024 07:48AM
|
Apr 20th, 2024 11:54PM
|
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
|
Open
|
Biotechnology, Life sciences, Human micro biome, Cholesterol management, Disease prevention, Obesity prevention, Obesity management, Diabetes prevention, and Health & wellbeing
|
Open
|
|
York
|
|
GB
|
YO10 5DG
|
|
OptiBiotix Health
|
|
|
|
lon:opti
|
19679023
|
Apr 19th, 2024 12:00AM
|
OptiBiotix Health Plc
|
2.0K
|
15.00
|
Open
|
|
Apr 19th, 2024 10:21AM
|
Apr 19th, 2024 10:21AM
|
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
|
Open
|
Biotechnology, Life sciences, Human micro biome, Cholesterol management, Disease prevention, Obesity prevention, Obesity management, Diabetes prevention, and Health & wellbeing
|
Open
|
|
York
|
|
GB
|
YO10 5DG
|
|
OptiBiotix Health
|
|
|
|
lon:opti
|
19679023
|
Apr 18th, 2024 12:00AM
|
OptiBiotix Health Plc
|
2.0K
|
15.00
|
Open
|
|
Apr 18th, 2024 09:00AM
|
Apr 19th, 2024 06:46AM
|
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
|
Open
|
Biotechnology, Life sciences, Human micro biome, Cholesterol management, Disease prevention, Obesity prevention, Obesity management, Diabetes prevention, and Health & wellbeing
|
Open
|
|
York
|
|
GB
|
YO10 5DG
|
|
OptiBiotix Health
|
|
|
|
lon:opti
|
19679023
|
Apr 17th, 2024 12:00AM
|
OptiBiotix Health Plc
|
2.0K
|
15.00
|
Open
|
|
Apr 17th, 2024 09:01PM
|
Apr 17th, 2024 09:01PM
|
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
|
Open
|
Biotechnology, Life sciences, Human micro biome, Cholesterol management, Disease prevention, Obesity prevention, Obesity management, Diabetes prevention, and Health & wellbeing
|
Open
|
|
York
|
|
GB
|
YO10 5DG
|
|
OptiBiotix Health
|
|
|
|
lon:opti
|
19679023
|
Apr 16th, 2024 12:00AM
|
OptiBiotix Health Plc
|
2.0K
|
15.00
|
Open
|
|
Apr 16th, 2024 07:57AM
|
Apr 16th, 2024 05:18PM
|
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
|
Open
|
Biotechnology, Life sciences, Human micro biome, Cholesterol management, Disease prevention, Obesity prevention, Obesity management, Diabetes prevention, and Health & wellbeing
|
Open
|
|
York
|
|
GB
|
YO10 5DG
|
|
OptiBiotix Health
|
|
|
|
lon:opti
|
19679023
|
Apr 15th, 2024 12:00AM
|
OptiBiotix Health Plc
|
2.0K
|
15.00
|
Open
|
|
Apr 15th, 2024 10:41AM
|
Apr 16th, 2024 04:41AM
|
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
|
Open
|
Biotechnology, Life sciences, Human micro biome, Cholesterol management, Disease prevention, Obesity prevention, Obesity management, Diabetes prevention, and Health & wellbeing
|
Open
|
|
York
|
|
GB
|
YO10 5DG
|
|
OptiBiotix Health
|
|
|
|
lon:opti
|
19679023
|
Apr 14th, 2024 12:00AM
|
OptiBiotix Health Plc
|
1.9K
|
15.00
|
Open
|
|
Apr 14th, 2024 06:42AM
|
Apr 14th, 2024 06:42AM
|
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
|
Open
|
Biotechnology, Life sciences, Human micro biome, Cholesterol management, Disease prevention, Obesity prevention, Obesity management, Diabetes prevention, and Health & wellbeing
|
Open
|
|
York
|
|
GB
|
YO10 5DG
|
|
OptiBiotix Health
|
|
|
|
lon:opti
|
19679023
|
Apr 13th, 2024 12:00AM
|
OptiBiotix Health Plc
|
1.9K
|
15.00
|
Open
|
|
Apr 13th, 2024 05:36AM
|
Apr 13th, 2024 05:36PM
|
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
|
Open
|
Biotechnology, Life sciences, Human micro biome, Cholesterol management, Disease prevention, Obesity prevention, Obesity management, Diabetes prevention, and Health & wellbeing
|
Open
|
|
York
|
|
GB
|
YO10 5DG
|
|
OptiBiotix Health
|
|
|
|
lon:opti
|
19679023
|
Apr 12th, 2024 12:00AM
|
OptiBiotix Health Plc
|
1.9K
|
15.00
|
Open
|
|
Apr 12th, 2024 05:50AM
|
Apr 12th, 2024 02:45PM
|
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
|
Open
|
Biotechnology, Life sciences, Human micro biome, Cholesterol management, Disease prevention, Obesity prevention, Obesity management, Diabetes prevention, and Health & wellbeing
|
Open
|
|
York
|
|
GB
|
YO10 5DG
|
|
OptiBiotix Health
|
|
|